JP2017508737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508737A5 JP2017508737A5 JP2016552579A JP2016552579A JP2017508737A5 JP 2017508737 A5 JP2017508737 A5 JP 2017508737A5 JP 2016552579 A JP2016552579 A JP 2016552579A JP 2016552579 A JP2016552579 A JP 2016552579A JP 2017508737 A5 JP2017508737 A5 JP 2017508737A5
- Authority
- JP
- Japan
- Prior art keywords
- mcg
- csf
- days
- analog
- retinoid agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 47
- 239000000556 agonist Substances 0.000 claims description 46
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 46
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 42
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 22
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000003714 granulocyte Anatomy 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 208000004235 neutropenia Diseases 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 8
- DFVSWRJUJYWJKB-UHFFFAOYSA-N icosa-4,7,10,13-tetraynoic acid Chemical compound CCCCCCC#CCC#CCC#CCC#CCCC(O)=O DFVSWRJUJYWJKB-UHFFFAOYSA-N 0.000 claims description 8
- 229950010130 tamibarotene Drugs 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 7
- 239000013074 reference sample Substances 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 5
- PNAWUIKCVQSLFG-UHFFFAOYSA-N 4-[(4-chloro-3-hydroxy-5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-carbonyl)amino]-2,6-difluorobenzoic acid Chemical compound C1=C2C(C)(C)CCC(C)(C)C2=C(Cl)C(O)=C1C(=O)NC1=CC(F)=C(C(O)=O)C(F)=C1 PNAWUIKCVQSLFG-UHFFFAOYSA-N 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 210000000440 neutrophil Anatomy 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- 208000025212 Constitutional neutropenia Diseases 0.000 claims description 2
- 206010051645 Idiopathic neutropenia Diseases 0.000 claims description 2
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 201000001546 cyclic hematopoiesis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 23
- 229940079593 drug Drugs 0.000 claims 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461941233P | 2014-02-18 | 2014-02-18 | |
| US61/941,233 | 2014-02-18 | ||
| PCT/US2015/016447 WO2015126989A1 (en) | 2014-02-18 | 2015-02-18 | Compositions and methods for treating neutropenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017508737A JP2017508737A (ja) | 2017-03-30 |
| JP2017508737A5 true JP2017508737A5 (OSRAM) | 2018-03-29 |
Family
ID=53878925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552579A Pending JP2017508737A (ja) | 2014-02-18 | 2015-02-18 | 好中球減少症の治療用の組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10286039B2 (OSRAM) |
| EP (1) | EP3107533A4 (OSRAM) |
| JP (1) | JP2017508737A (OSRAM) |
| KR (1) | KR20160113302A (OSRAM) |
| CN (1) | CN106413701A (OSRAM) |
| AU (1) | AU2015219038B2 (OSRAM) |
| CA (1) | CA2937340C (OSRAM) |
| MX (1) | MX2016010699A (OSRAM) |
| RU (1) | RU2016136833A (OSRAM) |
| WO (1) | WO2015126989A1 (OSRAM) |
| ZA (1) | ZA201605109B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104519879B (zh) | 2012-06-07 | 2018-10-02 | 洛杉矶儿童医院 | 使用类视色素激动剂治疗中性粒细胞减少症的方法 |
| US10286039B2 (en) | 2014-02-18 | 2019-05-14 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
| CN107130026B (zh) * | 2017-05-15 | 2018-03-09 | 新疆医科大学第四附属医院 | 一种结直肠癌诊断和治疗效果评价相关的基因 |
| WO2019079339A1 (en) * | 2017-10-18 | 2019-04-25 | Avalon Flaviviral Therapeutics (Hk) Limited | COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY |
| CN112390731B (zh) * | 2020-11-16 | 2022-11-25 | 成都大学 | 一种具有多靶点的维甲酸类衍生物及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691196A (en) | 1992-12-31 | 1997-11-25 | American Cyanamid Company | Recombinant nucleic acid containing a response element |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| EP0957918A1 (en) | 1996-12-19 | 1999-11-24 | American Cyanamid Company | Method of treating or inhibiting neutropenia |
| JP4799803B2 (ja) | 2000-09-08 | 2011-10-26 | マサチューセッツ インスティテュート オブ テクノロジー | Ｇ−ｃｓｆアナログ組成物および方法 |
| US7119061B2 (en) | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| AU2003902308A0 (en) | 2003-05-14 | 2003-05-29 | Diagnose It Pty Ltd | A method and system for the monitoring of medical conditions |
| AU2004238146A1 (en) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or remedy for diseases accompanied by tissue destruction |
| EP1621191A1 (en) | 2004-07-29 | 2006-02-01 | Werner Bollag | Treatment of inflammatory diseases by RXR Antagonists |
| BRPI0514343A (pt) | 2004-08-13 | 2008-06-10 | Anormed Inc | combinações de quimiocinas para mobilizar células progenitoras/tronco |
| UA91204C2 (ru) | 2004-12-02 | 2010-07-12 | Ману Чаудхарі | Композиция для преодоления опосредствованной бета-лактамазой резистентности к антибиотикам с использованием ингибитора бета-лактамазы, предназначенная для инъекции |
| WO2006071451A2 (en) | 2004-12-03 | 2006-07-06 | The Regents Of The University Of California | Compounds that prevent macrophage apoptosis and uses thereof |
| ES2702128T3 (es) | 2006-05-16 | 2019-02-27 | Io Therapeutics Llc | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación |
| NZ580209A (en) | 2007-03-30 | 2011-11-25 | Tmrc Co Ltd | Tamibarotene capsule preparation |
| JP2011505386A (ja) | 2007-12-06 | 2011-02-24 | シーエスエル、リミテッド | 白血病性幹細胞の阻害方法 |
| EP2604702B1 (en) * | 2008-09-05 | 2015-07-01 | The University of Chicago | Methods for direct detection of DNA damage |
| AU2010309388B2 (en) | 2009-10-19 | 2016-03-10 | Laila Nutraceuticals | Extracts, fractions and compositions comprising acetogenins and their applications |
| RU2446173C1 (ru) | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
| CN102380090A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
| EP2673358B1 (en) | 2011-02-08 | 2019-01-09 | FUJIFILM Cellular Dynamics, Inc. | Hematopoietic precursor cell production by programming |
| US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| US20150147309A1 (en) | 2012-06-06 | 2015-05-28 | Fondazione Telethon | Allosteric chaperones and uses thereof |
| CN104519879B (zh) | 2012-06-07 | 2018-10-02 | 洛杉矶儿童医院 | 使用类视色素激动剂治疗中性粒细胞减少症的方法 |
| US20160172942A1 (en) | 2013-07-04 | 2016-06-16 | Linak A/S | Actuator system |
| US10286039B2 (en) | 2014-02-18 | 2019-05-14 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
-
2015
- 2015-02-18 US US15/119,339 patent/US10286039B2/en active Active
- 2015-02-18 KR KR1020167025068A patent/KR20160113302A/ko not_active Withdrawn
- 2015-02-18 EP EP15751576.8A patent/EP3107533A4/en not_active Withdrawn
- 2015-02-18 CA CA2937340A patent/CA2937340C/en active Active
- 2015-02-18 WO PCT/US2015/016447 patent/WO2015126989A1/en not_active Ceased
- 2015-02-18 MX MX2016010699A patent/MX2016010699A/es unknown
- 2015-02-18 CN CN201580009151.6A patent/CN106413701A/zh active Pending
- 2015-02-18 AU AU2015219038A patent/AU2015219038B2/en not_active Ceased
- 2015-02-18 JP JP2016552579A patent/JP2017508737A/ja active Pending
- 2015-02-18 RU RU2016136833A patent/RU2016136833A/ru not_active Application Discontinuation
-
2016
- 2016-07-21 ZA ZA2016/05109A patent/ZA201605109B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508737A5 (OSRAM) | ||
| JP2013533858A5 (OSRAM) | ||
| JP2014528474A5 (OSRAM) | ||
| JP2018520189A5 (OSRAM) | ||
| JP2014528901A5 (OSRAM) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2011190199A (ja) | 関節リウマチ薬 | |
| JP2013526611A5 (OSRAM) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| RU2016136833A (ru) | Композиции и способы для лечения нейтропении | |
| JP2016505050A5 (OSRAM) | ||
| CN1913902A (zh) | 使用喹硫平抗精神病药物治疗精神疾病 | |
| JPWO2019241442A5 (OSRAM) | ||
| CN1287855C (zh) | B型慢性肝炎治疗剂 | |
| JP2019535830A5 (OSRAM) | ||
| CN104758304B (zh) | 三七皂苷r1的医药用途 | |
| CN1179726C (zh) | 柚皮苷在制备支持性治疗非典型性肺炎药物中的应用 | |
| US8198293B2 (en) | Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases | |
| JP2021091608A5 (OSRAM) | ||
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP2015520759A5 (OSRAM) | ||
| RU2013155476A (ru) | Композиции и способы изменения фенотипов xlhed | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 |